← Back to Clinical Trials
Recruiting NCT05875870

NCT05875870 Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05875870
Status Recruiting
Phase
Sponsor Taipei Veterans General Hospital, Taiwan
Condition Lung Neoplasm
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2023-07-24
Primary Completion 2028-05-15

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Daylight exposure combine walkingStretching exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2023-07-24 with a primary completion date of 2028-05-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study plans to investigate the effectiveness of six-week light exposure combined with an exercise training program on improving sleep-wake rhythm, physical and mental symptoms, quality of life, one-year recurrence rate, and one-year survival rate of patients with lung and esophageal cancer.

Eligibility Criteria

Inclusion Criteria: 1. Patients with newly diagnosed primary lung cancer or esophageal cancer, from the first stage to the third stage. 2. At least 20 years of age. 3. Able to communicate in Mandarin Chinese or Taiwanese. 4. Literate and free from cognitive disabilities. 5. The attending physician agrees to participate in the study. 6. Those who can connect to the Internet with mobile devices such as computers, mobile phones, and tablets, or those whose family members can assist in the operation. 7. Those with Karnofsky Performance Scale (KPS) greater than or equal to 70 points. 8. Those who are hospitalized for lung cancer or esophageal cancer lesion resection. Exclusion Criteria: 1. Congestive heart failure. 2. Orthopedic diseases of the lower extremities that limit one's walking ability.

Contact & Investigator

Central Contact

Hui-Mei Chen, PhD

✉ alice@ntunhs.edu.tw

📞 886-2-28227101

Principal Investigator

Hui-Mei Chen, PhD

PRINCIPAL INVESTIGATOR

National Taipei University of Nursing and Health Sciences

Frequently Asked Questions

Who can join the NCT05875870 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, studying Lung Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05875870 currently recruiting?

Yes, NCT05875870 is actively recruiting participants. Contact the research team at alice@ntunhs.edu.tw for enrollment information.

Where is the NCT05875870 trial being conducted?

This trial is being conducted at Taipei City, Taiwan, Taipei, Taiwan.

Who is sponsoring the NCT05875870 clinical trial?

NCT05875870 is sponsored by Taipei Veterans General Hospital, Taiwan. The principal investigator is Hui-Mei Chen, PhD at National Taipei University of Nursing and Health Sciences. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology